Nuvalent NUVL 深 滬
等待開盤 09-23 09:30:00 美东时间
123.96
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 123.96
- 總市值 98.09亿
- 52周最高 123.99
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 71.13
- 委 比 0.00%
- 總股本 7912.82万
- 歷史最高 123.99
- 量 比 0
- 振 幅 0.00%
- 歷史最低 7.09
- 每 手 1
- 風險率 10.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多GSK启动六部分美元债券发行，为Nuvalent收购案融资
葛兰素史克正在推销美元债券，以帮助为其106亿美元收购美国生物技术公司Nuvalent Inc.的过桥融资进行再融资。此前该制药商已完成了35亿欧元（约合41亿...
09-08 20:53
MNC百亿并购逻辑变了
原标题：MNC百亿并购逻辑变了 来源：动脉网 2026年全球医药领域百亿级并购热度重回高位： 6月艾伯维109亿美元拿下Apogee、GSK斥资106亿美元收...
08-21 09:09
Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Zenas BioPharma reported financial results for Q2 2026 and provided updates on its pipeline. The FDA accepted the BLA for obexelimab to treat IgG4-RD with a PDUFA date of May 27, 2027. New bioequivalence data for obexelimab's delivery methods were confirmed. Phase 2 SunStone SLE trial results are expected in Q4 2026. ZB021's Phase 1 trial is ongoing, with initial data anticipated by year-end. Four abstracts for orelabrutinib were accepted for MST...
08-13 11:00
Fortress Biotech Q2 Earnings Preview
Fortress Biotech (FBIO) is scheduled to announce Q2 earnings results on Wednesday, August 12th, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $18.3M (+...
08-12 05:35
GSK declares $0.4518/ADS or 17p/share dividend
GSK (GSK) declares approx. $0.4518 per ADS or 17.00p/share interim dividend, in line with previous, bringing total dividend declared to 70p/share for full year 2026. Payable Oct. 8; for shareholders o...
07-28 20:34
GSK announces $2.5B cost savings program to fund R&D
With its consensus-beating Q2 2026 results on Tuesday, GSK (GSK) announced a three-year program to reduce annual expenditure by £1.9B ($2.5B) in a bid to fund investment in its late-stage pipeline and...
07-28 20:01
GSK Non-GAAP EPS of £0.51 beats by £0.02, revenue of £8.41B beats by £4.05B; reaffirms FY2026 outlook
GSK press release (GSK): Q2 Non-GAAP EPS of £0.51 beats by £0.02. Revenue of £8.41B (+5.3% Y/Y) beats by £4.05B. Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £...
07-28 19:24
ViiV's Dovato as effective as Gilead's Biktarvy in head-to-head trial
ViiV Healthcare, which is majority owned by GSK (GSK), said that a head-to-head study of its HIV treatment Dovato (dolutegravir/lamivudine), which contains two drugs, is as effective as Gilead Science...
07-28 01:44
GSK Wins FDA Approval For Jideytro To Treat Previously Treated ROS1-Positive Non-Small Cell Lung Cancer
GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase...
07-23 00:41
Trevi climbs after late-stage trial setback for GSK cough therapy
After GSK (GSK) announced it would discontinue a chronic cough therapy following a late-stage trial failure, Trevi Therapeutics (TRVI), which is advancing a rival candidate, traded higher to reach an ...
07-18 02:04
